Granulocyte colony-stimulating factor therapy and systemic inflammation in critically ill patients

Takala, Aino K.; Pettilä, Ville; Takkunen, O.; Rintala, Esa; Kautiainen, Hannu; Repo, Heikki

doi:10.1007/s00011-005-1340-2

Cited by 3 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are conflicting reports on the effects of G-CSF on IL-10 in adults as in neonates; so, no additional interpretation is offered. 43 None of our subjects treated with rhG-CSF acquired an infection in the subsequent 28 days, suggesting a possible prophylactic benefit of prior exposure as previously proposed. 12 Additionally, these reports noted the possibility that other indirect benefits might occur through an initially unanticipated effect of rhG-CSF on the inflammatory process itself.…”

Section: Discussionsupporting

confidence: 58%

Can Recombinant Granulocyte Colony Stimulating Factor Modulate Inflammatory Response in Extreme Low Gestational Age Newborns?: Effect of rhG-CSF on Cytokines in ELGAN

Kocherlokata¹,

Crow

Vakkalanka

et al. 2017

J Pediatr Infect Dis

View full text Add to dashboard Cite

Background Elevated levels of cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are common in critically ill neonates, and may contribute to organ-based injury during acute illness contributing to neurodevelopmental delay. In both animals and human adults, recombinant human granulocyte-colony stimulating factor (rhG-CSF) is associated with a reduction in TNF-α blood levels. Objective We aim to determine whether rhG-CSF treatment affects the blood levels of proinflammatory cytokines, TNF-α and IL-6 or the anti-inflammatory cytokine, IL-10 in extremely-low-gestational age neonates (ELGANs) compared with conventional medical management. Methods The study included three groups of ELGANs between 2 and 4 days of age as subjects. Control group (n = 5); treated, nonseptic group (n = 10); and treated, septic group (n = 5) neonates were treated with conventional measures. In addition, the test subjects were treated with 10 μg/kg/d of rhG-CSF intravenously for 3 consecutive days. The levels of TNF-α, IL-6, and IL-10 were measured before and 24 hours after completion of the study. Results The average TNF-α levels increased after birth in control subjects but did not rise in rhG-CSF treated subjects. A nonsignificant decrease of IL-6 and IL-10 blood levels was noted in all the subjects independent of the drug treatment. Conclusion The use of rhG-CSF is associated with lower TNF-α levels in ELGANs. Speculation During critical illness or sepsis, rhG-CSF may have unanticipated benefits as a drug that can elevate neutrophil number and function in neonates while simultaneously limiting collateral injury due to TNF-α.

show abstract

Section: Discussionsupporting

confidence: 58%

Can Recombinant Granulocyte Colony Stimulating Factor Modulate Inflammatory Response in Extreme Low Gestational Age Newborns?: Effect of rhG-CSF on Cytokines in ELGAN

Kocherlokata¹,

Crow

Vakkalanka

et al. 2017

J Pediatr Infect Dis

View full text Add to dashboard Cite

show abstract

“…For this substudy, the clinical data comprised of APACHE II [14], SOFA -score [15,16], admission diagnosis, and laboratory values for white blood cell (WBC), neutrophil count and inflammatory mediators: (Interleukin (IL)-6, Interleukin (IL)-10, soluble E-selectin (sE-selectin) and soluble Interleukin 2 receptor (sIL-2R) from baseline and day 3 [17]. …”

Section: Methodsmentioning

confidence: 99%

Heparin binding protein in patients with acute respiratory failure treated with granulocyte colony-stimulating factor (filgrastim) – a prospective, placebo-controlled, double-blind study

et al. 2013

View full text Add to dashboard Cite

BackgroundHeparin Binding Protein (HBP) is released to blood circulation from activated neutrophils in bacterial infections. It is a potential inducer of vascular leakage and precludes the development of septic shock. Filgrastim induces the production of new neutrophils and modulates their bacterial-killing activity. We evaluated the effect of filgrastim on HBP –concentrations in critically ill patients with acute respiratory failure.Methods59 critically ill patients with acute respiratory failure were included in this randomised, double-blind, placebo-controlled study of filgrastim 300 micrograms/day or corresponding placebo for 7 days. Plasma samples were drawn on baseline, day 4 and day 7. HBP –concentrations, absolute leukocyte and neutrophil counts were measured.ResultsThe median [IQR] HBP concentrations were 23.6 ng/ml [13.9-43.0 ng/ml], 25.1 ng/ml [17.7-35.5 ng/ml] and 15.9 ng/ml [12.6-20.7 ng/ml] in patients receiving filgrastim on baseline, day 4 and day 7, respectively. The HBP concentrations in placebo group were 21.6 ng/ml [16.9-28.7 ng/ml], 13.9 ng/ml [12.0-19.5 ng/ml] and 17.8 ng/ml [13.6-20.9 ng/ml]. At day 4, the filgrastim group had significantly higher HBP –concentrations when compared to placebo group (p < 0.05). No correlation between HBP –concentrations and absolute neutrophil count or P/F –ratios was found.ConclusionsFilgrastim treatment is associated with increased circulating HBP levels compared to placebo, but the absolute neutrophil count or the degree of oxygenation failure did not correlate with the observed plasma HBP –concentrations.Trial registrationClinicaltrials.gov NCT01713309

show abstract

“…Takala and colleagues [1] investigated the effect of therapy with granulocyte colony-stimulating factor (G-CSF) fi lgrastim on systemic infl ammation by determination of levels of soluble E-selectin, interleukin(IL)-10, IL-6, and soluble IL-2 receptor in patients with pneumonia, sepsis and other infections.…”

mentioning

confidence: 99%

“…However, upregulation of such anti-infl ammatory factors as soluble tumour necrosis factor(TNF)-a receptor type I and II, and IL-1 receptor antagonist by G-CSF [3] may be the main anti-infl ammatory effect and more important than the infl uence of G-CSF on IL-10 [4]. In the present study by Takala et al [1] data on the infl uence of a short-term G-CSF therapy on other anti-infl ammatory factors are lacking. The reported reduction of IL-10 levels in the G-CSF-treated group was subtle and did not affect clinical course.…”

mentioning

confidence: 99%

Granulocyte colony-stimulating factor therapy and systemic inflammation: effect on interleukin-10

Wiedermann

2005

Inflamm. res.

View full text Add to dashboard Cite

Granulocyte colony-stimulating factor therapy and systemic inflammation in critically ill patients

Abstract: Filgrastim prolongs endothelial activation and possibly inhibits development of immune suppression mediated by IL-10.

Cited by 3 publications

References 39 publications

Can Recombinant Granulocyte Colony Stimulating Factor Modulate Inflammatory Response in Extreme Low Gestational Age Newborns?: Effect of rhG-CSF on Cytokines in ELGAN

Can Recombinant Granulocyte Colony Stimulating Factor Modulate Inflammatory Response in Extreme Low Gestational Age Newborns?: Effect of rhG-CSF on Cytokines in ELGAN

Heparin binding protein in patients with acute respiratory failure treated with granulocyte colony-stimulating factor (filgrastim) – a prospective, placebo-controlled, double-blind study

Granulocyte colony-stimulating factor therapy and systemic inflammation: effect on interleukin-10

Contact Info

Product

Resources

About